Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 62332-092

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 62332-092). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil 10 mg

Product name: Donepezil Hydrochloride tablets. Each bottle contains 30 tablets with the strength of 5 mg. It is a prescription medication that requires a valid prescription from a licensed healthcare professional. The manufacturer is Alembic Pharmaceuticals Limited. The label shows the National Drug Code (NDC) number 62332-093-30. The medication should be dispensed to the patient as directed by the healthcare professional.*

FDA Label Image

Donepezil Figur11

This appears to be a table of data related to the change from baseline in the treatment of an unspecified condition with two different doses of Donepezil hydrochloride (23mg/day and 10mg/day) over a period of 24 weeks. The table shows the LS mean and SE, as well as the percentage improvement or decline over the course of treatment. However, without further information it is impossible to provide a more specific or useful description.*

FDA Label Image

Donepezil Figur12

The text shows a graph presenting the cumulative percentage of patients using two doses of Donepezil hydrochloride (23 mg/day and 10mg/day) and the corresponding SIB (Severe Impairment Battery) change from baseline. The graph indicates that at 100%, only 4 patients were observed to have positive changes. The highest percentage of patients experienced a change of around 20-30% while others experienced no change or a decrease in their SIB scores.*

FDA Label Image

Donepezil Figur13

FDA Label Image

Figure 1 (Donepezil Figure1)

FDA Label Image

Figure 10 (Donepezil Figure10)

This is a graph labeled "Cumulative Percentage of Patients" with the title "ADCS-ADL Change from Baseline". The graph shows the percentage of patients who completed 6 months of double-blind treatment with particular changes from baseline in ADCS-ADL-Severe scores. The X-axis shows the score range from 0 to 50 and the Y-axis shows the cumulative percentage of patients. The text labels the graph as Figure 10.*

FDA Label Image

Figure 2 (Donepezil Figure2)

FDA Label Image

Figure 3 (Donepezil Figure3)

This is a graph showing the frequency distribution of scores for the CIBIC-plus rating at Week 24. The CIBIC-plus rating includes categories such as markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse.*

FDA Label Image

Figure 4 (Donepezil Figure4)

The text is a part of a figure description from a study on drug treatment for patients (possibly with cognitive impairment) and shows a graph depicting the time-course of change from baseline ADAS-cog score over the span of 15 weeks. No further information is available.*

FDA Label Image

Figure 5 (Donepezil Figure5)

FDA Label Image

Figure 6 (Donepezil Figure6)

FDA Label Image

Figure 7 (Donepezil Figure7)

FDA Label Image

Figure 8 (Donepezil Figure8)

The text describes a figure labeled as "Figure 8" that presents the cumulative percentage of patients who completed 6 months of double-blind treatment and their changes from baseline in SIB scores. The figure includes five points labeled as "i," "20," "15," "45," "a0," and "48," which appear to represent different levels of change in the SIB scores. No further information is available.*

FDA Label Image

Donepezil mg5

FDA Label Image

Structure (Donepezil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.